Popular Trials
Fibroblast Growth Factor 21 (FGF21) Analog
Efruxifermin for Nonalcoholic Steatohepatitis
This trial is testing a medication called efruxifermin to see if it can help people with a specific liver disease called NASH. The study focuses on patients whose disease has not yet progressed to cirrhosis. The medication works by reducing inflammation and fat in the liver to improve its health.
HMG-CoA Reductase Inhibitor
Statins for Non-alcoholic Steatohepatitis (NASH)
This trial will test whether or not a daily dose of atorvastatin (a type of statin) is effective in treating NASH and hepatic fibrosis, and whether it is safe. The results of this study will help design a larger study on the matter.
Thiazolidinedione
Low-Dose Pioglitazone for NASH
This trial is testing a small daily dose of pioglitazone in patients with type 2 diabetes and a specific liver condition called NASH. The goal is to see if this medication can improve their liver health by helping their bodies manage blood sugar and fat levels better.
Popular Filters
Trials for NAFLD Patients
Glucagon-like peptide-1 (GLP-1) receptor agonist
Efinopegdutide for Nonalcoholic Steatohepatitis (NASH)
This trial is testing a new medicine called efinopegdutide to see if it can help people with a liver disease called non-alcoholic steatohepatitis (NASH). Researchers want to find out if this medicine can reduce the symptoms of NASH without making liver scarring worse. They are also checking how safe the medicine is and how well people can tolerate it.
Behavioural Intervention
Low-Fructose Diet for Fatty Liver Disease in Youth
This trial will compare how two different diets (high vs low in high fructose corn syrup or HFCS) may affect how much fat gets deposited in the liver and whether or not a lower diet in HFCS can help decrease liver damage in adolescents with non-alcoholic fatty liver disease (NAFLD).
Trials for Non-alcoholic Fatty Liver Disease Patients
Glucagon-like peptide-1 (GLP-1) receptor agonist
Efinopegdutide for Nonalcoholic Steatohepatitis (NASH)
This trial is testing a new medicine called efinopegdutide to see if it can help people with a liver disease called non-alcoholic steatohepatitis (NASH). Researchers want to find out if this medicine can reduce the symptoms of NASH without making liver scarring worse. They are also checking how safe the medicine is and how well people can tolerate it.
Behavioural Intervention
Low-Fructose Diet for Fatty Liver Disease in Youth
This trial will compare how two different diets (high vs low in high fructose corn syrup or HFCS) may affect how much fat gets deposited in the liver and whether or not a lower diet in HFCS can help decrease liver damage in adolescents with non-alcoholic fatty liver disease (NAFLD).
Phase 3 Trials
Thyroid Hormone Receptor Agonist
Resmetirom for Fatty Liver Disease
This trial is testing a medication called MGL-3196 to see if it can help treat patients with NASH and liver fibrosis. The medication works by reducing fat and inflammation in the liver, which can help heal and protect it from further damage.
Hormone Therapy
Estrogen Therapy for NASH in Postmenopausal Women
This trial will study the effect of the hormone estradiol on non-alcoholic steatohepatitis (NASH) in post-menopausal women. NASH is a growing epidemic in the United States with limited treatment options.
Glucagon-like peptide-1 receptor agonist
Semaglutide for Non-alcoholic Steatohepatitis
This trial is studying a medication called semaglutide in patients with NASH. Semaglutide is a well-known medication used to treat type 2 diabetes, and participants will either receive semaglutide or a dummy medication, with no way of knowing which they're getting. The study will last for 5 years, during which participants will have to inject themselves weekly and will have 21 clinic visits and 9 phone calls with clinical staff. Some of the clinic visits may last more than one day.
Galectin Inhibitor
Belapectin for NASH Cirrhosis
This trial is testing belapectin, a medication aimed at helping people with a severe liver condition called NASH cirrhosis. The study focuses on patients who have high blood pressure in their liver but no swollen veins in their esophagus. Belapectin works by reducing liver inflammation and scarring, which can improve liver function and reduce health problems.
Thyroid Hormone Receptor Agonist
Resmetirom for NASH Cirrhosis
This trial tests a daily pill called resmetirom for people with a stable form of liver disease not caused by alcohol. The goal is to see if the drug can improve liver function and reduce liver fat, thereby preventing serious complications. Resmetirom has been tested in previous studies for the treatment of liver disease.
Trials With No Placebo
Behavioural Intervention
Low-Fructose Diet for Fatty Liver Disease in Youth
This trial will compare how two different diets (high vs low in high fructose corn syrup or HFCS) may affect how much fat gets deposited in the liver and whether or not a lower diet in HFCS can help decrease liver damage in adolescents with non-alcoholic fatty liver disease (NAFLD).
View More Related Trials
Frequently Asked Questions
Introduction to nash
What are the top hospitals conducting nash research?
In the realm of clinical trials for Nonalcoholic Steatohepatitis (NASH), several hospitals have emerged as key players in the battle against this complex liver condition. Located in Lakewood Ranch, Florida, the Florida Research Institute takes a leading role with six active NASH trials and an impressive total of 17 trials dedicated to this disease. Having initiated their first trial in 2016, they are committed to exploring innovative treatment options for patients affected by NASH. Similarly, South Texas Research Institute in Edinburg has also made significant strides with six ongoing NASH trials and a commendable history of 14 completed studies since recording their inaugural trial just two years ago in 2019.
Meanwhile, at Inland Empire Liver Foundation situated in Rialto, California researchers are actively engaged in six NASH clinical trials while having conducted an extensive range of 28 previous investigations since initiating their first one back in 2015. Another prominent player on this list is Tandem Clinical Research located in Marrero which currently runs six active NASH trials alongside a substantial contribution to scientific knowledge through conducting thirteen previous studies; theirs can be traced back only four years ago to2017.The American Research Corporation located within San Antonio may appear slightly smaller-scale but nevertheless plays a crucial part with its five current NASH clinical trials and noteworthy involvement through eleven previously held investigations that began around the same time frame.
These top hospitals spearhead efforts not only to understand and combat NASH but also signify triumphs of medical advancement on both regional and national levels. Each step taken towards unraveling the intricacies surrounding this liver condition brings us closer to discovering effective treatments that could positively impact countless lives worldwide
Which are the best cities for nash clinical trials?
For NASH clinical trials, several cities emerge as top contenders in the field of research and development. San Antonio, Texas leads with an impressive 69 active trials focusing on promising treatments like TERN-501, TVB-2640, and AXA1125. Following closely behind is Miami, Florida with 56 ongoing studies exploring IVA337, Study 1 ALN-HSD Low Dose, Obeticholic Acid, among others. Houston, Texas also plays a notable role in NASH research with 30 active trials investigating TERN-501, TVB-2640, BOS-580 and more. These cities provide crucial platforms for individuals seeking to participate in cutting-edge NASH clinical trials that pave the way for advancements in therapy options and potential breakthroughs in care.
Which are the top treatments for nash being explored in clinical trials?
Cutting-edge research in clinical trials is shedding light on the top treatments for non-alcoholic steatohepatitis (NASH), a liver disease with limited therapeutic options. Two leading contenders include EFX and empagliflozin. EFX, introduced in 2019, has shown promise with two ongoing NASH trials and three all-time trials dedicated to this condition. Similarly, empagliflozin, which made its debut in 2015, is also being explored through two active NASH trials and boasts an impressive record of eight all-time NASH studies. These innovative therapies offer hope for patients battling this complex liver disease as scientists continue to uncover potential breakthroughs.
What are the most recent clinical trials for nash?
Exciting advancements are being made in the field of nash treatment, with recent clinical trials offering hope and potential solutions for patients. One such trial is Part 1 Group 2, a Phase 2 study that aims to evaluate the efficacy and safety of a new intervention for nash. Additionally, BI 3006337 dose group 4, a Phase 1 trial, has shown promise as a potential treatment option for this condition. Pemvidutide at a dosage of 1.2 mg has also demonstrated positive outcomes in Phase 2 studies with nash patients. Furthermore, efinopegdutide at a dosage of 4mg is currently undergoing Phase 2 trials to assess its effectiveness against nash. Finally, TVB-2640 at a dosage of50 mg holds potential as an intervention for individuals with normal hepatic function affected by nash.This ongoing research offers renewed optimism to those living with this challenging disease
What nash clinical trials were recently completed?
In recent years, numerous clinical trials have been completed in the search for effective treatments for nonalcoholic steatohepatitis (NASH). Notable trials include Altimmune's investigation of ALT-801, which concluded in September 2021 and March 2022. Likewise, 89bio's trial on BIO89-100 and Merck Sharp & Dohme Corp.'s study on Efinopegdutide were both finalized in August 2021. Other studies such as Amgen's AMG 609 trial, Terns' TERN-201 trial, and Pfizer's PF-06865571 trial reached completion between May to August of 2021. These groundbreaking efforts highlight the collective commitment towards advancing NASH therapeutics and offer hope for patients grappling with this complex condition.